Pursuant to the OUI/MRC License, we obtained from OUI and MRC an exclusive, royalty-bearing, sublicensable with consent (through one tier) license under certain patent rights, or the OUI/MRC Patents,…
The License Agreement provides the Company with an exclusive world wide license to licensed data and technology owned by OUI and MRC in respect of cell-penetrating peptides for the treatment of Duche…
The License Agreement provides the Company with an exclusive world wide license to licensed data and technology owned by OUI and MRC in respect of cell-penetrating peptides for the treatment of Duche…
Entities affiliated with RA Capital Management, L.P., or RA Capital, purchased common stock in the Company's IPO in May 2022, the Company's 2024 Offering in February 2024, and the Company's 2025 Offe…